Oaktree Specialty Lending Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCSL research report →
Range $11 – $12.5
Price Chart
About the company
Oaktree Specialty Lending Corporation (OCSL) functions as a business development company (BDC), dedicated to providing capital solutions for middle-market businesses. Its investment strategy involves a diverse array of financing types, including interim bridge loans, various tiers of secured debt (first and second lien, senior and junior), unsecured loans, hybrid mezzanine debt, and preferred equity stakes. These funds are primarily deployed to support growth initiatives such as corporate expansions, acquisitions led by private equity sponsors, and management buyouts within small and mid-sized enterprises.
- CEO
- Armen Panossian
- IPO
- 2008
- HQ
- Los Angeles, CA, US
AI snapshot
Six angles, distilled from the data.
OCSL is still in a sideways-to-down regime after losing momentum from its 52-week range. The shares sit just below both the 50-day and 200-day moving averages, with the longer trend still acting as overhead resistance rather than support.
Wall Street is cautious but not bearish: the consensus is Hold with a $12.50 target, modestly above the current share price. Recent changes have leaned toward maintenance and trimming, including a new Market Perform call and prior target cuts to $13 and $12, which keeps expectations restrained.
The earnings pattern has improved, with four straight EPS beats and a 5-for-8 beat rate overall. Next-year EPS estimates still point higher to 1.3612 from 0.48 TTM, so shareholders should watch whether credit performance and distributable earnings keep supporting that path.
Insiders have been net buyers, and the activity is concentrated in open-market purchases rather than automatic awards. Multiple directors and officers bought shares across 2025 and 2026, including sizable purchases from the president, co-CIO, and board members, which signals internal confidence in the setup.
Profitability is solid for a lending vehicle, with an operating margin of 82.76% and net margin of 14.45%. Growth is softer, with revenue down 7.8% year over year and earnings down 19.3%, while leverage remains elevated at $1.487 billion of debt against $79.63 million of cash.
OCSL screens as a higher-yield specialty lender with a 13.71% free-cash-flow yield and a 7.53 P/E, which keeps valuation reasonable versus the broader financials group. The tradeoff is weaker growth and a balance sheet that is more debt-heavy than many asset managers.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.03B
- P/E
- 25.51
- Fwd P/E
- 8.82
- PEG
- 1.42
- P/S
- 4.15
- P/B
- 0.76
- EV/EBITDA
- 13.06
- Div Yield
- 12.43%
- Gross Margin
- 78.66%
- Op Margin
- 47.35%
- Net Margin
- 16.05%
- ROE
- 2.89%
- ROIC
- 4.02%
Latest fiscal year · YoY change
- Revenue
- $209.26M-30.2%
- Gross Profit
- $169.78M-35.0%
- Op Income
- $141.66M
- Net Income
- $40.28M+18.8%
- EPS
- $0.46+17.9%
- OCF Growth
- +24.5%
- FCF Growth
- +24.5%
- 52W High
- $13.91
- 52W Low
- $10.63
- 50D MA
- $12.01
- 200D MA
- $12.06
- Beta
- 0.58
- RSI (14)
- 41
- Avg Volume
- 446.34K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Oaktree Specialty Lending ended fiscal 2026 with stable leverage and improved non-accruals, while lower income and a modestly smaller portfolio trimmed quarterly earnings.· November 17, 2026
- Non-accruals fell to about 1.8% of the debt portfolio at fair value, down about 120 bps year over year and from $81 million to $45 million in fair value dollars.
- Adjusted net investment income was $29.6 million, or $0.34 per share, versus $32.2 million, or $0.37 per share, last quarter.
- The board declared a $0.32 quarterly dividend, made up of a $0.30 base dividend and a $0.02 supplemental dividend.
- Leverage stayed conservative at 1.00x net debt to equity, with about $1.04 billion of liquidity at quarter end and about $689 million pro forma after the 2027 notes are repaid.
- Management said the September rate hike should lift earnings going forward, with every 25 bps increase in base rates adding a little over $0.05 per share per quarter once fully reset.
Fourth fiscal quarter adjusted total investment income was $68.0 million, down from $69.2 million in the prior quarter. Adjusted net investment income was $29.6 million, or $0.34 per share, versus $32.2 million, or $0.37 per share, in the prior quarter; for the full fiscal year, adjusted net investment income was $131.7 million, or $1.49 per share, versus $151.3 million, or $1.76 per share in fiscal 2025. NAV per share was $15.63 at September 30, down 0.4% from $15.70 in June. Non-accruals were about 1.8% of the debt portfolio at fair value, and adjusted total investment income for the year was $281.4 million versus $315.4 million last year. The company guided that the September rate hike will begin to flow through in the December quarter; once fully reset, every 25 bps increase in base rates adds a little over $0.05 per share per quarter to adjusted net investment income. Management also reiterated a long-term leverage target of 0.9x to 1.25x and said liquidity was about $1.04 billion at quarter end, or about $689 million pro forma for repayment of the 2027 notes.
Management’s tone was constructive and focused on execution. Matt Pendo emphasized progress on the two main priorities for the year: reducing non-accruals and keeping the balance sheet flexible. He also said fiscal 2027 priorities are unchanged: resolve non-accruals, exit non-income-producing equity positions, and redeploy proceeds into performing assets. Armen Panossian framed the macro backdrop as higher for longer, but said Oaktree’s underwriting is built around fundamental credit analysis rather than macro forecasting, and he highlighted that the firm is positioned to benefit from floating-rate assets if base rates remain elevated.
Chris McKown said the quarter’s earnings decline was mainly due to a lower average portfolio balance and a higher income-based incentive fee. He noted the incentive fee paid was $4.8 million in the quarter versus $2.4 million last quarter, and that the total return hurdle reduced fees by about $1.2 million this quarter and $16.1 million over the last year. He also pointed out that 91% of debt investments are floating rate and 100% are floating or swapped to floating, so the September rate hike should lift net investment income as resets roll through, with the majority of the impact expected in the December quarter.
Analysts asked about the decline in PIK income, and management said it was driven mainly by BioXcel moving to non-accrual and the exit of a royalty interest that had been paying PIK. Questions also focused on capital allocation, and Matt Pendo said priority one is deploying capital into attractive loans rather than buying back shares, while staying within the 0.9x to 1.25x leverage range. On portfolio quality, management said recent problem credits are increasingly idiosyncratic rather than tied to a broad post-COVID normalization theme, citing an opioid treatment center business with ERP-related revenue collection issues as an example.
The company ended the year with much lower non-accrual dollars, conservative leverage, and ample liquidity, giving management room to be opportunistic. Earnings should improve as higher base rates flow through the largely floating-rate book, and management believes the remaining stressed credits can still see progress.
Quarterly earnings softened, with adjusted net investment income down and full-year income below the prior year. Deal flow remains below last year, and management still has unresolved non-accruals, including Pluralsight and the newly added BioXcel exposure, even though they expect BioXcel to resolve quickly.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 88.09M
- Float Shares
- 87.68M
of shares held by institutions
174 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Brookfield Corp | 7.87M | ▲ 7.87M |
| Oaktree Capital Management LP | 7.87M | ▲ 6.02M |
| Private Management Group Inc | 4.01M | ▲ 140.85K |
| Royal Bank Of Canada | 3.03M | ▲ 110.40K |
| Morgan Stanley | 2.50M | ▲ 100.73K |
| Bruni J V & Co /Co | 2.46M | ▼ 9.82K |
| Ares Management LLC | 2.38M | ▲ 179.80K |
| Generali Asset Management Spa Sgr | 2.09M | ▲ 7.10K |
| Ubs Group AG | 2.07M | ▼ 8.61K |
| Van Eck Associates Corp | 1.98M | ▼ 215.30K |
| Claret Asset Management Corp | 1.76M | ▲ 90.27K |
| Russell Investments Group, Ltd. | 1.08M | ▲ 26.41K |
Held by 21 ETFs
Biggest fund positions in OCSL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 12, 26 | Panossian Armen | buy | 1,700 |
| Mar 16, 26 | CALDWELL PHYLLIS R | buy | 2,500 |
| Mar 16, 26 | Gero Deborah Ann | buy | 2,000 |
| Dec 31, 25 | McKeone Brett | other | 0 |
| Sep 15, 25 | CALDWELL PHYLLIS R | buy | 975 |
| Sep 15, 25 | CALDWELL PHYLLIS R | buy | 25 |
| Sep 15, 25 | CALDWELL PHYLLIS R | buy | 2,000 |
| Jun 30, 25 | Gero Deborah Ann | buy | 2,500 |
| May 15, 25 | Panossian Armen | buy | 8,000 |
| May 7, 25 | CALDWELL PHYLLIS R | buy | 2,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OCSL coverage
Recent articles, reports, and earnings notes.

Oaktree Specialty Lending (OCSL): Credit Recovery Supports Hold
Oaktree Specialty Lending offers a discounted income play with improving credit quality, but softer earnings and a leveraged balance sheet keep the case at Hold. NAV support and lower non-accruals help, yet upside looks limited near consensus value.

Oaktree Specialty Lending Corporation (OCSL) slips on deep dive
Oaktree Specialty Lending Corporation (OCSL) slips despite a narrow EPS beat and revenue in line with estimates. This deep-dive earnings analysis looks beyond the headline to examine declining quarterly EPS, improving credit quality, portfolio yield, leverage, liquidity, and what the latest results may signal for the stock.

Oaktree Specialty Lending Corporation (OCSL) slips on earnings beats
Oaktree Specialty Lending Corporation (OCSL) slips even as it beats earnings expectations, with investors weighing the latest results and outlook for the specialty lender.
Want a deeper read on OCSL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Implied Volatility Surging for Oaktree Specialty Lending Stock Options
zacks.com · Nov 20
Oaktree Specialty Lending: Another Dividend Cut Is Likely Coming (Rating Downgrade)
seekingalpha.com · Nov 20
Oaktree Specialty Lending: I Love The 11% Yield, But There's One Big Problem
seekingalpha.com · Nov 17
Oaktree Specialty Lending Corporation (OCSL) Q4 2026 Earnings Call Transcript
seekingalpha.com · Nov 17
What Oaktree Specialty Lending (OCSL) Said on Its Q4 Earnings Call
marketbeat.com · Nov 17
Oaktree Specialty Lending (OCSL) Meets Q4 Earnings Estimates
zacks.com · Nov 17
Oaktree Specialty Lending Corporation Announces Fourth Fiscal Quarter and Full Year 2026 Financial Results
businesswire.com · Nov 17
11% Dividend Yield: What The Market Misses About My Biggest Position
seekingalpha.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 17, 2026 · Live quote · Not investment advice